ACTU (Actuate Therapeutics) 3-1 Month Momentum %: 13.37% (As of Jul. 13, 2026)


ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.58
View Full Analysis

What is Actuate Therapeutics 3-1 Month Momentum %?

Actuate Therapeutics ACTU +30.55% 14 3-1 Month Momentum % is 13.37% as of Jul. 13, 2026. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 1,389 Biotechnology companies, Actuate Therapeutics ranks better than 83.95% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-13), Actuate Therapeutics's 3-1 Month Momentum % is 13.37%.

The industry rank for Actuate Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

ACTU's 3-1 Month Momentum % is ranked better than
83.95% of 1389 companies
in the Biotechnology industry
Industry Median: -11.38 vs ACTU: 13.37

Actuate Therapeutics  (NAS:ACTU) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Actuate Therapeutics 3-1 Month Momentum % Related Terms

ACTU vs RNXT, ESLA, APLM: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Actuate Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's 3-1 Month Momentum % falls into.


ACTU
14GF Score
Actuate Therapeutics Inc ACTU
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics  (NAS:ACTU) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 13.37% mean?
Actuate Therapeutics (ACTU) has a 3-1 Month Momentum % of 13.37% as of Jul. 13, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Actuate Therapeutics and its competitors. According to the industry distribution chart, Actuate Therapeutics ranks #223 out of 1389 companies in the Biotechnology industry, placing it in the top 16.1%.
Is Actuate Therapeutics' 3-1 Month Momentum % too high?
Actuate Therapeutics' current 3-1 Month Momentum % is 13.37%. Based on the distribution chart, Actuate Therapeutics ranks #223 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' 3-1 Month Momentum % compare to RNXT and ESLA?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #223 out of 1389 companies for 3-1 Month Momentum %. This places Actuate Therapeutics in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current 3-1 Month Momentum % is 13.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current 3-1 Month Momentum % of 13.37%. The current 3-1 Month Momentum % is 13.37%. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current 3-1 Month Momentum % is 13.37% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.58
Price